RARE - Ultragenyx Pharmaceutical GAAP EPS of -$2.26 misses by $0.49 revenue of $89.34M beats by $2.01M

• Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q2 GAAP EPS of -$2.26 misses by $0.49 .
• Revenue of $89.34M (+2.7% Y/Y) beats by $2.01M .
• As of June 30, 2022, cash, cash equivalents, and marketable debt securities were $706.1 million
• Outlook: The company continues to expect 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.

For further details see: